CI Scientists’ Post

🚀 Exciting Developments in Antibody Drug Conjugates (ADCs) ! 🔬 🔔 Follow our page for interesting ADC updates! 🌟 Explore the latest edition of ADC Digest for this week of December 2024, featuring groundbreaking advancements in the field of Antibody Drug Conjugates. 💊 Suven Pharmaceuticals acquires controlling stake in US-based NJ Bio 💊 GSK multiple myeloma drug’s DREAMM comeback continues with phase 3 data at ASH 💊 Merck’s investigational zilovertamab vedotin in combination with R-CHP demonstrates complete response rate of 100% at 1.75 mg/kg dose in phase 2 trial of previously untreated patients with DLBCL 💊 NextCure announces acceptance of IND application for LNCB74 💊 Next-generation ADC treatments that will overcome the limitations and resistance of existing ADCs 💊 Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer 💊 Blenrep (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma #CIScientists #ADC #MedicalInnovations #Innovation #ADCnews #Antibodydrugconjugate #cancer #competitiveintelligence

CAR T cells are cell-based #genetherapies that have in many respects revolutionized #oncology care. Although these therapies were initially approved as third-line therapies for relapsed or refractory myelomas or lymphomas, they are increasingly studied as treatments for patient populations earlier in the disease progression as well as new types of tumor (including solid tumors) and non-oncology indications. FDA's final guidance (specific to ex-vivo modified CAR Ts for oncology indications including solid tumors as well as hematological malignancies) provides a useful overview of key considerations including chemistry manufacturing and controls (#CMC), non-clinical testing, and clinical testing considerations and the Q&A during the #FDA webinar was insightful. One of the key take-aways for me: the field of #CARTs is evolving rapidly; new and increasingly complex processes are used to generate CAR Ts including the use of gene editing processes; and our understanding of long-term safety and efficacy is still developing while improvements in #CMC can shorten the time between apheresis and CAR-T administration and make off-the-shelf products more feasible.

Want to learn more about FDA’s final guidance on considerations for the development of CAR T cell products? Check out the recording of OTP’s latest webinar for key takeaways, changes from the draft guidance, answered questions from registrants & more: https://bit.ly/49H4zHd 

Excited to see Ab Studio’s first outlicensed Fc+ TCE asset, GB261 got a new deal by the licensee (Genorbio): https://lnkd.in/gis8nSSa Happy to see the first baby from our patent granted Fc+ TCE platform will move forward to autoimmune disease field. Since the world’s first Fc+ TCE, Catumaxomab, showed dose dependent hepatotoxicity in patients with EPCAM-positive cancers and one patient died from acute liver failure after receiving 10ug of catumaxomab, almost all major players in the TCE field either removed or silenced Fc effector function. GB261 is the world’s second Fc+ TCE entered into clinical trials and the world’s first Fc+ TCE showed great safety, efficacy balance in human at as high as 300mg dosage. The clinical POC data suggested that Ab Studio’s computer aided design platform could resolve challenges that traditional technologies can not. We hope our platforms, technologies and new assets to be outlicensed continue to support more partners!

2024 has already been a "blink and you'll miss a radiopharma deal" kind of year. If Trump's term does loosen up M&A in 2025, watch out for more. There are plenty of acquisition targets about, each offering different pieces of the RLT pie: isotopes, chelator technology, novel delivery vehicles or binders, target expertise or even combination modalities (like DDR agents). https://lnkd.in/e_aCj4dJ

Check out the latest research on the adenosine A2A receptor, part of the rhodopsin-like GPCR family. This study reveals the X-ray crystal structure of the partial agonist LUF5834 in complex with A2AR, uncovering crucial binding pocket interactions and water networks. Discover how partial agonists like LUF5834 can bind to both active and inactive receptor conformations, offering new perspectives on GPCR drug discovery! Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox. ➡️https://bit.ly/3ViDghM #GPCR #DrGPCR

Consistent management of #ProstateCancer trials utilizing RECIST 1.1 with PCWG 2 or 3 criteria is not trivial. The recent addition of PSMA-PET adds further to the complexity of reliably addressing treatment response. Learn why you can trust Calyx #MedicalImaging. https://lnkd.in/e7iFt3ZZ #ClinicalTrials #ChooseCalyx

Immutep (ASX:IMM) reports positive topline results from TACTI-003 Phase 2b trial - IMMUTEP #ASX

MetaVia has announced positive top-line 16-week results from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed MASH. In this trial, DA-1241 (100mg) demonstrated a statistically significant reduction in ALT levels at weeks 4 and 8, with a near statistically significant reduction at week 16. Read more in the press release: https://bit.ly/MTVADA1241

ZYTIGA (Abiraterone) and XTANDI (enzalutamide) are standards of care options for the first line mCRPC patients progressing on androgen deprivation therapy (ADT). No combination has been so far approved to increase the radiological progression-free survival (rPFS) and overall survival (OS) in first-line mCRPC.  Data from a Phase III PEACE-3 (NCT02194842) comparative study of enzalutamide vs a combination of Radium-223 (Ra223) investigating whether the combination improves cancer progression over enzalutamide alone in patients with mCRPC was presented in the Proffered Paper Session at the ESMO - European Society for Medical Oncology 2024. Unlock Comprehensive Analysis and Expert Insights with DelveInsight's Exclusive ESMO 2024 Coverage @ https://lnkd.in/gZam4XRc #esmo #esmo2024 #esmoconference #conference #esmocoverage #detailedinsights #pharma #pharmaceutical